ロード中...
Landmark Studies Impacting the Medical Management of Benign Prostatic Hyperplasia
The treatment of benign prostatic hyperplasia (BPH) has changed dramatically over the past 10 years. Phase 3 studies of the safety and effectiveness of α-blockers (eg, terazosin and doxazosin) and 5-α-reductase inhibitors (eg, finasteride) for the treatment of BPH began to appear in the literature i...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MedReviews, LLC
2003
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1502353/ https://ncbi.nlm.nih.gov/pubmed/16985962 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|